Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, Republic of Korea.
BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, Republic of Korea.
Sci Rep. 2021 Jun 7;11(1):11981. doi: 10.1038/s41598-021-91445-3.
There is an unmet need for new influenza vaccine strategies that compensate for impaired vaccine responses in elderly individuals. Here, we evaluated the effectiveness of a single-stranded RNA (ssRNA) as an adjuvant to enhance the efficacy of inactivated influenza vaccine (IIV) in mouse models. Immunization with the ssRNA along with IIV reduced viral titers as well as pathological and inflammatory scores in the lungs after influenza challenge in aged mice. ssRNA induced balanced Th1/Th2 responses with an increase in IgA titers. Moreover, the ssRNA adjuvant markedly increased the frequency of influenza HA-specific T cells and IFN-γ production along with the expression of genes related to innate and adaptive immune systems that could overcome immunosenescence in aged mice. Our findings indicate that ssRNA is an efficient vaccine adjuvant that boosts cellular and humoral immunity in aged mice, demonstrating its potential as a novel adjuvant for currently available influenza virus vaccines for elderly individuals.
老年人对流感疫苗的反应受损,因此需要新的流感疫苗策略来满足这一需求。在这里,我们评估了单链 RNA (ssRNA) 作为佐剂增强灭活流感疫苗 (IIV) 在小鼠模型中的功效。在流感病毒攻击后,与 IIV 一起免疫接种 ssRNA 可降低老年小鼠肺部的病毒滴度以及病理和炎症评分。ssRNA 诱导了平衡的 Th1/Th2 反应,IgA 滴度增加。此外,ssRNA 佐剂显著增加了流感 HA 特异性 T 细胞的频率和 IFN-γ 的产生,同时还表达了与固有和适应性免疫系统相关的基因,这可能克服了老年小鼠的免疫衰老。我们的研究结果表明,ssRNA 是一种有效的疫苗佐剂,可增强老年小鼠的细胞和体液免疫,为目前用于老年人的流感病毒疫苗提供了一种新的佐剂选择。